Extended Data Fig. 5: LpIMB19 and RHP enhance infiltration and activation of melanoma-specific CD8 T cells.
Rag1 mice were inoculated with 2x105 B16F10 melanoma cells subcutaneously and engrafted intravenously with 1:1 mixture of antigen-specific Pmel-1Thy1.1 and OT-1Thy1.1 CD8 T cells. a, Experimental scheme (top) and tumor progression of B16F10 melanoma in mice treated with PBS (n = 5) or LpIMB19 (n = 6) or RHP (n = 8). b, Flow cytometry diagram (top) and quantitation of frequency of Pmel-1 and OT-1 CD8 T cells in melanomas (n = 5 for PBS, n = 6 for LpIMB19, and n = 7 for RHP). c–f, Flow cytogram (top) and quantitation of IFN-γhi (c), TNFhi (d), PD-1hi (e), and Tim3hi (f) CD8 T cells in tumor-infiltrating melanoma antigen-specific Pmel-1 TCRVβ13+ CD8 T cells (n = 5 for PBS, n = 6 for LpIMB19, and n = 7 for RHP). Results are pooled from two independent experiments. Data are mean ± SEM. Statistical analyses were performed using two-way ANOVA (a) or two-tailed paired Student’s t-test (b) or two-tailed unpaired Student’s t-test (c-f).
